Oral vancomycin for clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant

2022 ◽  
Author(s):  
Olivia J. Altemeier ◽  
Kelsey T. Konrardy
Keyword(s):  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Oral Vancomycin ◽  
Hematopoietic Cell Transplant ◽  
Clostridioides Difficile

scholarly journals Effectiveness of bezlotoxumab for prevention of recurrent Clostridioides difficile infection among transplant recipients

2021 ◽  
Author(s):  
Tanner M Johnson ◽  
Amanda H Howard ◽  
Matthew A Miller ◽  
Lorna L Allen ◽  
Misha Huang ◽  
...  
Keyword(s):  
Organ Transplant ◽  
Standard Of Care ◽  
Hematopoietic Cell ◽  
Solid Organ ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Solid Organ Transplant Recipients

Abstract Background Bezlotoxumab significantly reduces the incidence of recurrent Clostridioides difficile infection; however, limited data is available in solid-organ and hematopoietic-cell transplant recipients. Methods We conducted a single-center retrospective analysis comparing recurrent Clostridioides difficile infection in solid-organ and hematopoietic-cell transplant recipients receiving standard of care alone (oral vancomycin, fidaxomicin, or metronidazole) or bezlotoxumab plus standard of care. The primary outcome was 90-day incidence of recurrent Clostridioides difficile infection, and secondary outcomes included 90-day hospital readmission, mortality, and incidence of heart failure exacerbation. Results Overall, 94 patients received bezlotoxumab plus standard of care (n=38) or standard of care alone (n=56). The mean age was 53 years, patients had a median of 3 prior Clostridioides difficile episodes, and 4 risk factors for recurrent infection. Most patients were solid-organ transplant recipients (76%), with median time to index Clostridioides difficile infection occurring 2.7 years post-transplantation. Ninety-day recurrent Clostridioides difficile infection occurred in 16% (6/38) in the bezlotoxumab cohort compared to 29% (16/56) in the standard of care cohort (p=0.13). Multivariable regression revealed bezlotoxumab was associated with significantly lower odds of 90-day recurrent Clostridioides difficile infection (Odds Ratio [95% CI]: 0.28 [0.08-0.91]). There were no differences in secondary outcomes, and no heart failure exacerbations were observed. Conclusions In a cohort of primarily solid-organ transplant recipients, bezlotoxumab was well tolerated and associated with lower odds of recurrent Clostridioides difficile infection at 90-days. Larger, prospective trials are needed to confirm these findings amongst solid-organ and hematopoietic-cell transplant populations.

Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients

2019 ◽  
Vol 71 (7) ◽  
pp. 1693-1700 ◽  
Author(s):  
Wesley S Rogers ◽  
Lars F Westblade ◽  
Rosemary Soave ◽  
Stephen G Jenkins ◽  
Koen van Besien ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Chain Reaction ◽  
Hematopoietic Cell Transplant ◽  
Clostridioides Difficile ◽  
Multiplexed Pcr ◽  
Clostridioides Difficile Infection ◽  
Polymerase Chain ◽  
The Impact

Abstract Background Diarrhea is common and associated with substantial morbidity among hematopoietic cell transplant (HCT) recipients, but the etiology is often not identified. Multiplexed polymerase chain reaction (PCR) assays increase the detection of diarrheal pathogens, but the impact of this technology in this population has not been evaluated. Methods Our center replaced stool cultures and other conventional microbiologic methods with the FilmArray Gastrointestinal Panel (GI PCR) in June 2016. We reviewed all adult patients who received an HCT from June 2014–May 2015 (pre–GI PCR, n = 163) and from June 2016–May 2017 (post–GI PCR, n = 182) and followed them for 1 year after transplantation. Clostridioides difficile infection was diagnosed by an independent PCR test in both cohorts. Results The proportion of patients with ≥1 identified infectious diarrheal pathogen increased from 25% to 37% after implementation of GI PCR (P = .01). Eight patients (5%) in the pre–GI PCR cohort tested positive for a pathogen other than C. difficile versus 49 patients (27%) in the post–GI PCR cohort (P < .001). The most common non–C. difficile diarrheal pathogens in the post–GI PCR cohort were enteropathogenic Escherichia coli (n = 14, 8%), norovirus (n = 14, 8%), and Yersinia enterocolitica (n = 7, 4%). The percentage of diarrheal episodes with an identified infectious etiology increased from 14% to 23% (P = .001). Median total costs of stool testing per patient did not increase (pre: $473; post: $425; P = .25). Conclusions Infectious etiologies of diarrhea were identified in a higher proportion of HCT recipients after replacing conventional stool testing with a multiplexed PCR assay, without an increase in testing costs.

scholarly journals Evaluation of the National Healthcare Safety Network standardized infection ratio risk adjustment for healthcare-facility-onset Clostridioides difficile infection in intensive care, oncology, and hematopoietic cell transplant units in general acute-care hospitals

2020 ◽  
Vol 41 (4) ◽  
pp. 404-410 ◽  
Author(s):  
Christopher R. Polage ◽  
Kathleen A. Quan ◽  
Keith Madey ◽  
Frank E. Myers ◽  
Debbra A. Wightman ◽  
...  
Keyword(s):  
Intensive Care ◽  
Acute Care ◽  
Risk Adjustment ◽  
Tertiary Care ◽  
Acute Care Hospitals ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Hematopoietic Cell Transplant ◽  
General Hospitals ◽  
Clostridioides Difficile

AbstractObjective:To evaluate the National Health Safety Network (NHSN) hospital-onset Clostridioides difficile infection (HO-CDI) standardized infection ratio (SIR) risk adjustment for general acute-care hospitals with large numbers of intensive care unit (ICU), oncology unit, and hematopoietic cell transplant (HCT) patients.Design:Retrospective cohort study.Setting:Eight tertiary-care referral general hospitals in California.Methods:We used FY 2016 data and the published 2015 rebaseline NHSN HO-CDI SIR. We compared facility-wide inpatient HO-CDI events and SIRs, with and without ICU data, oncology and/or HCT unit data, and ICU bed adjustment.Results:For these hospitals, the median unmodified HO-CDI SIR was 1.24 (interquartile range [IQR], 1.15–1.34); 7 hospitals qualified for the highest ICU bed adjustment; 1 hospital received the second highest ICU bed adjustment; and all had oncology-HCT units with no additional adjustment per the NHSN. Removal of ICU data and the ICU bed adjustment decreased HO-CDI events (median, −25%; IQR, −20% to −29%) but increased the SIR at all hospitals (median, 104%; IQR, 90%–105%). Removal of oncology-HCT unit data decreased HO-CDI events (median, −15%; IQR, −14% to −21%) and decreased the SIR at all hospitals (median, −8%; IQR, −4% to −11%).Conclusions:For tertiary-care referral hospitals with specialized ICUs and a large number of ICU beds, the ICU bed adjustor functions as a global adjustment in the SIR calculation, accounting for the increased complexity of patients in ICUs and non-ICUs at these facilities. However, the SIR decrease with removal of oncology and HCT unit data, even with the ICU bed adjustment, suggests that an additional adjustment should be considered for oncology and HCT units within general hospitals, perhaps similar to what is done for ICU beds in the current SIR.

scholarly journals Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function

2020 ◽  
Vol 26 (9) ◽  
pp. 1597-1606
Author(s):  
Gena G. Foster ◽  
Michael J. Grant ◽  
Samantha M. Thomas ◽  
Blake Cameron ◽  
Doug Raiff ◽  
...  
Keyword(s):  
Renal Function ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Hematopoietic Cell Transplant ◽  
Allogeneic Hematopoietic Cell Transplant

scholarly journals Clinical Validation of the Definitions of Resistant and Refractory Cytomegalovirus (CMV) Infection and Disease in Hematopoietic Cell Transplant (HCT) Recipients.

2019 ◽  
Vol 25 (3) ◽  
pp. S343
Author(s):  
Marjorie V. Batista ◽  
Annette Artau ◽  
Samuel L Aitken ◽  
Fareed Khawaja ◽  
Firas EL Chaer ◽  
...  
Keyword(s):  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Clinical Validation ◽  
Cmv Infection ◽  
Hematopoietic Cell Transplant

scholarly journals Penicillin Allergy Skin Testing as an Antibiotic Stewardship Intervention in Hematopoietic Cell Transplant Recipients

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S266-S267 ◽  
Author(s):  
Christopher Kovacs ◽  
Vasilios Athans ◽  
David Lang ◽  
Ronald Sobecks ◽  
Lisa Rybicki ◽  
...  
Keyword(s):  
Antibiotic Stewardship ◽  
Skin Testing ◽  
Hematopoietic Cell ◽  
Penicillin Allergy ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant ◽  
Allergy Skin Testing
Sign in / Sign up

Export Citation Format

Share Document